Matches in SemOpenAlex for { <https://semopenalex.org/work/W3138972026> ?p ?o ?g. }
- W3138972026 endingPage "1369" @default.
- W3138972026 startingPage "1369" @default.
- W3138972026 abstract "High-grade serous ovarian carcinoma (HGSOC) is the deadliest of gynecological cancers due to its high recurrence rate and acquired chemoresistance. RAS/MEK/ERK pathway activation is linked to cell proliferation and therapeutic resistance, but the role of MEK1/2-ERK1/2 pathway in HGSOC is poorly investigated. We evaluated MEK1/2 pathway activity in clinical HGSOC samples and ovarian cancer cell lines using immunohistochemistry, immunoblotting, and RT-qPCR. HGSOC cell lines were used to assess immediate and lasting effects of MEK1/2 inhibition with trametinib in vitro. Trametinib effect on tumor growth in vivo was investigated using mouse xenografts. MEK1/2 pathway is hyperactivated in HGSOC and is further stimulated by cisplatin treatment. Trametinib treatment causes cell cycle arrest in G1/0-phase and reduces tumor growth rate in vivo but does not induce cell death or reduce fraction of CD133+ stem-like cells, while increasing expression of stemness-associated genes instead. Transient trametinib treatment causes long-term increase in a subpopulation of cells with high aldehyde dehydrogenase (ALDH)1 activity that can survive and grow in non-adherent conditions. We conclude that MEK1/2 inhibition may be a promising approach to suppress ovarian cancer growth as a maintenance therapy. Promotion of stem-like properties upon MEK1/2 inhibition suggests a possible mechanism of resistance, so a combination with CSC-targeting drugs should be considered." @default.
- W3138972026 created "2021-03-29" @default.
- W3138972026 creator A5005097620 @default.
- W3138972026 creator A5008481783 @default.
- W3138972026 creator A5016839332 @default.
- W3138972026 creator A5017050408 @default.
- W3138972026 creator A5023939998 @default.
- W3138972026 creator A5041133745 @default.
- W3138972026 creator A5050845789 @default.
- W3138972026 creator A5054490790 @default.
- W3138972026 creator A5062655798 @default.
- W3138972026 creator A5062734340 @default.
- W3138972026 date "2021-03-18" @default.
- W3138972026 modified "2023-10-11" @default.
- W3138972026 title "The MEK1/2 Pathway as a Therapeutic Target in High-Grade Serous Ovarian Carcinoma" @default.
- W3138972026 cites W1490956705 @default.
- W3138972026 cites W1848470479 @default.
- W3138972026 cites W1976033985 @default.
- W3138972026 cites W1976246361 @default.
- W3138972026 cites W1977776332 @default.
- W3138972026 cites W1978070868 @default.
- W3138972026 cites W1978167160 @default.
- W3138972026 cites W1983833034 @default.
- W3138972026 cites W1991401350 @default.
- W3138972026 cites W2004384654 @default.
- W3138972026 cites W2006456243 @default.
- W3138972026 cites W2017975901 @default.
- W3138972026 cites W2018569307 @default.
- W3138972026 cites W2021429824 @default.
- W3138972026 cites W2029189318 @default.
- W3138972026 cites W2030329983 @default.
- W3138972026 cites W2039785378 @default.
- W3138972026 cites W2050206485 @default.
- W3138972026 cites W2051960191 @default.
- W3138972026 cites W2062069198 @default.
- W3138972026 cites W2062289724 @default.
- W3138972026 cites W2066113694 @default.
- W3138972026 cites W2067067209 @default.
- W3138972026 cites W2074982201 @default.
- W3138972026 cites W2075711878 @default.
- W3138972026 cites W2087670396 @default.
- W3138972026 cites W2087793237 @default.
- W3138972026 cites W2090973422 @default.
- W3138972026 cites W2095945017 @default.
- W3138972026 cites W2108244474 @default.
- W3138972026 cites W2114843025 @default.
- W3138972026 cites W2114852376 @default.
- W3138972026 cites W2115954319 @default.
- W3138972026 cites W2126087169 @default.
- W3138972026 cites W2127808743 @default.
- W3138972026 cites W2132526578 @default.
- W3138972026 cites W2137542308 @default.
- W3138972026 cites W2137990944 @default.
- W3138972026 cites W2141258764 @default.
- W3138972026 cites W2144169031 @default.
- W3138972026 cites W2144796447 @default.
- W3138972026 cites W2148799267 @default.
- W3138972026 cites W2149441684 @default.
- W3138972026 cites W2155156801 @default.
- W3138972026 cites W2157016650 @default.
- W3138972026 cites W2162922734 @default.
- W3138972026 cites W2162999937 @default.
- W3138972026 cites W2165280661 @default.
- W3138972026 cites W2187839502 @default.
- W3138972026 cites W2223921723 @default.
- W3138972026 cites W2305551225 @default.
- W3138972026 cites W2327657768 @default.
- W3138972026 cites W2343016248 @default.
- W3138972026 cites W2343870048 @default.
- W3138972026 cites W2408848642 @default.
- W3138972026 cites W2569695585 @default.
- W3138972026 cites W2580035316 @default.
- W3138972026 cites W2616767884 @default.
- W3138972026 cites W2740089004 @default.
- W3138972026 cites W2762863290 @default.
- W3138972026 cites W2767305368 @default.
- W3138972026 cites W2770300603 @default.
- W3138972026 cites W2771491442 @default.
- W3138972026 cites W2772038399 @default.
- W3138972026 cites W2789416018 @default.
- W3138972026 cites W2799782832 @default.
- W3138972026 cites W2801604584 @default.
- W3138972026 cites W2807649309 @default.
- W3138972026 cites W2808770632 @default.
- W3138972026 cites W2811339164 @default.
- W3138972026 cites W2888060900 @default.
- W3138972026 cites W2894670618 @default.
- W3138972026 cites W2895729583 @default.
- W3138972026 cites W2897195059 @default.
- W3138972026 cites W2899159263 @default.
- W3138972026 cites W2903092572 @default.
- W3138972026 cites W2921707634 @default.
- W3138972026 cites W2946768587 @default.
- W3138972026 cites W2999417355 @default.
- W3138972026 cites W3006505133 @default.
- W3138972026 cites W3093649946 @default.
- W3138972026 cites W3117927179 @default.
- W3138972026 doi "https://doi.org/10.3390/cancers13061369" @default.